Antisense '97: a roundtable on the state of the industry.

Suppr

超能文献

出版信息

Nat Biotechnol. 1997 Jun;15(6):519-24. doi: 10.1038/nbt0697-519.

DOI:10.1038/nbt0697-519

PMID:9181572

Abstract

摘要

相似文献

Antisense '97: a roundtable on the state of the industry.

Nat Biotechnol. 1997 Jun;15(6):519-24. doi: 10.1038/nbt0697-519.

Antisense oligonucleotides: towards clinical trials.

Trends Biotechnol. 1996 Oct;14(10):376-87. doi: 10.1016/0167-7799(96)10053-6.

Antisense oligonucleotides: a new therapeutic approach.

Biotechnol Appl Biochem. 1997 Oct;26(2):65-71.

Antisense therapeutics.

Mol Med Today. 1996 May;2(5):184-5. doi: 10.1016/1357-4310(96)88763-6.

The new antibiotics.

Nat Biotechnol. 1999 Dec;17(12):1165-9. doi: 10.1038/70705.

Commentary: regulatory issues affecting oligonucleotides.

Antisense Res Dev. 1993 Fall;3(3):301-6. doi: 10.1089/ard.1993.3.301.

Antisense gene therapy trials underway in patients with CML.

Oncology (Williston Park). 1996 Sep;10(9):1411.

Antisense aims for a renaissance.

Science. 1997 May 23;276(5316):1192-3. doi: 10.1126/science.276.5316.1192.

Antisense oligonucleotide technology in the development of cancer therapeutics.

Cancer Gene Ther. 1994 Mar;1(1):65-71.

Redesigning NCI's clinical trials system: integration is the goal.

J Natl Cancer Inst. 2005 Jan 19;97(2):92-3. doi: 10.1093/jnci/97.2.92.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Antisense '97: a roundtable on the state of the industry.

Nat Biotechnol. 1997 Jun;15(6):519-24. doi: 10.1038/nbt0697-519.

Antisense oligonucleotides: towards clinical trials.

Trends Biotechnol. 1996 Oct;14(10):376-87. doi: 10.1016/0167-7799(96)10053-6.

Antisense oligonucleotides: a new therapeutic approach.

Biotechnol Appl Biochem. 1997 Oct;26(2):65-71.

Antisense therapeutics.

Mol Med Today. 1996 May;2(5):184-5. doi: 10.1016/1357-4310(96)88763-6.

The new antibiotics.

Nat Biotechnol. 1999 Dec;17(12):1165-9. doi: 10.1038/70705.

Commentary: regulatory issues affecting oligonucleotides.

Antisense Res Dev. 1993 Fall;3(3):301-6. doi: 10.1089/ard.1993.3.301.

Antisense gene therapy trials underway in patients with CML.

Oncology (Williston Park). 1996 Sep;10(9):1411.

Antisense aims for a renaissance.

Science. 1997 May 23;276(5316):1192-3. doi: 10.1126/science.276.5316.1192.

Antisense oligonucleotide technology in the development of cancer therapeutics.

Cancer Gene Ther. 1994 Mar;1(1):65-71.

Redesigning NCI's clinical trials system: integration is the goal.

J Natl Cancer Inst. 2005 Jan 19;97(2):92-3. doi: 10.1093/jnci/97.2.92.